WHO Pharmaceuticals Newsletter 1999, No. 01&02
(1999; 16 pages)
Table of Contents
Open this folder and view contentsRegulatory actions
Close this folderDrug surveillance
View the documentAcarbose: hepatitis: France, Spain
View the documentCorticosteroid-induced osteoporosis: guidelines available: UK
View the documentHydroxycarbamide: leg ulcers: review: France
View the documentMeasles/mumps/rubella (MMR) vaccine: no evidence of link with inflammatory bowel disease and/or autism: Ireland
View the documentMercury compounds: call for data: USA
View the documentNefazodone: review of adverse reactions: Australia
View the documentOndansetron: chest pain: Australia
View the documentPsorigon skin products: update: further analysis confirms tretinoin content: Germany
Open this folder and view contentsNew developments
Open this folder and view contentsGeneral information
Open this folder and view contentsMedication errors
Open this folder and view contentsVeterinary medicine
 

Measles/mumps/rubella (MMR) vaccine: no evidence of link with inflammatory bowel disease and/or autism: Ireland

Ireland. Concern has recently been expressed regarding a possible link between measles/mumps/rubella (MMR) vaccine and subsequent development of inflammatory bowel disease and/or autism in a very small number of children. The Irish Medicines Board has reviewed the available evidence and concluded that at present there is no evidence to support any link between the MMR vaccine and the subsequent development of either chronic inflammatory bowel disease or autism.

The MMR vaccine is highly effective and parents are strongly advised to continue to have their children immunized with this vaccine in accordance with current recommendations.

Reference: Irish Medicines Board, Drug Safety Newsletter, Issue No. 8, September 1998.

to previous section to next section
 

Last updated: May 3, 2013